… Clinic and Anixa Biosciences breast cancer vaccine trial.   Johnson received an experimental … shot is effective.  This trial will include 80 to 100 … receive the vaccine alongside standard treatments for breast cancer, including chemotherapy, immunotherapy …

… Government and Pharmac to provide more funding for early breast cancer medicines. Kāpiti … with advanced breast cancer two years after finishing treatment for early breast cancer, after experiencing …

… positive breast cancer patients, particularly in communication between oncologists, pharmacists, … leaving clinicians navigating complex treatment decisions with limited consensus … and transparent discussions about treatment costs. System-level interventions …

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation … progressed following treatment with a CDK4/6 inhibitor. The FDA provides … 3 ReDiscover-2 trial for patients with metastatic breast cancer and in a …

… other cancers, such as breast cancer (BRCA gene), biomarkers … doxorubicin pharmacokinetics and reduced cardiotoxicity compared to the free drug. … in the MPACT trial which demonstrated that providing … 47;about-cancer/treatment/drugs/pancreatic. Accessed September …

… of upwards of 30 FDA-approved breast cancer drugs, with additional advances expected … at-home treatment options for people with hormone receptor–positive breast cancer, potentially … clinic-based injections.1 Antibody-drug conjugates, which pair lab- …

… the US Food and Drug Administration (FDA) breakthrough therapy designation … +/HER2-) advanced breast cancer treatment. The designation covers adults with … II ReDiscover trial, which assessed the tolerability, safety, pharmacodynamics, pharmacokinetics, and …

In the evolving landscape of gastrointestinal (GI) oncology, the sequencing of antibody–drug conjugates (ADCs) is becoming a critical area of focus for clinicians as these agents move from trials into the clinic. In an interview with Targeted Oncology, …

Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, including failure of existing genetic models to …

… according to the company.¹ FDA typically reserves Priority Review … TROP2-directed DXd antibody drug conjugate (ADC) jointly … TROPION-Breast02 Phase III trial,¹ Datroway demonstrated a … Line Treatment For Patients With Wetastatic Triple-Negative Breast Cancer …